FDA December 2024 PCAC Review - Compounding Prohibited In December 2024, the U.S
Clinical data shows that Retatrutide preserves lean mass exceptionally well, and with adequate protein intake (0.8-1.0 grams per pound of body weight) and resistance training, muscle growth can occur alongside fat loss
This is particularly relevant for medications with narrow therapeutic windows
Some people report minor weight loss during their first week, but you shouldnt go into this process expecting those kinds of results its more common to start losing weight a few weeks into it and then up to two pounds each week (depending on your diet and exercise habits)
AVP is not a compounding pharmacy or outsourcing facility, and GLP-3 RT is not sold, marketed, or intended for use in humans
"Experimental Drug Yields Dramatic Weight Loss"